Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) has entered a licensing agreement with Attillaps Holdings, granting Glaukos an exclusive, global license to develop and commercialize Attillaps' investigational compounds targeting Demodex mites, which cause Demodex blepharitis and related ophthalmic diseases. This agreement enhances Glaukos' Corneal Health franchise and aims to address unmet medical needs in ophthalmology. Attillaps' lead compounds have shown promising preclinical results, although financial terms were not disclosed.
Glaukos Corporation (NYSE: GKOS) announced a settlement with Ivantis, Inc. regarding a patent infringement lawsuit initiated on April 14, 2018. As part of the agreement, Ivantis will pay Glaukos $60 million, with $30 million due by December 31, 2021 and another $30 million by December 31, 2022. Additionally, Ivantis will pay a 10% ongoing royalty through April 26, 2025. This settlement allows Glaukos to focus on its growth strategy and introduces mutual licenses between the companies.
Glaukos Corporation (NYSE: GKOS) has submitted a supplemental pre-market approval application to the FDA for its investigational device, the iStent infinite™ Trabecular Micro-Bypass System. This device aims to reduce intraocular pressure in patients with open-angle glaucoma who have not responded to prior treatments. The pivotal trial demonstrated a favorable safety profile, with 76% of participants achieving a 20% or greater reduction in pressure after 12 months. The announcement highlights Glaukos' commitment to advancing innovative solutions in glaucoma treatment.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company, will participate virtually in the Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 2:40 p.m. ET. The company focuses on innovative therapies for treating glaucoma and other eye disorders, including corneal and retinal diseases. The event will be accessible via webcast on Glaukos' Investor Relations website. Glaukos has pioneered Micro-Invasive Glaucoma Surgery (MIGS) and continues to develop its portfolio of surgical and pharmaceutical therapies.
Glaukos Corporation (NYSE: GKOS) announced a significant milestone with 200 peer-reviewed publications on the efficacy and safety of iStent technologies. This achievement includes over 20,000 analyzed eyes across nearly 20 years, with 183 independent studies and 11 randomized controlled trials. Key outcomes show a mean intraocular pressure reduction of 31.1% at 6-12 months and reduced medication burden post-surgery. The Journal of Glaucoma recognized a study highlighting these findings, reinforcing Glaukos's commitment to innovation in glaucoma treatment.
Glaukos Corporation (NYSE: GKOS) reported a remarkable 147% increase in net sales for Q2 2021, reaching $78.1 million compared to $31.6 million in Q2 2020. Key drivers included glaucoma net sales of $62.7 million and corneal health sales of $15.4 million. The gross margin improved to 77%, while operating expenses rose to $74.6 million. The net loss was reduced to $17.5 million or ($0.38) per diluted share, an improvement from $39.9 million in the previous year. The company expects net sales for 2021 to be between $285 million and $290 million.
Glaukos Corporation (NYSE: GKOS) announced its participation in the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from July 23–27, 2021, in Las Vegas. The company will sponsor an educational symposium titled “Innovation & Transformation in Glaucoma Management” on July 23, 2021. The event will showcase important presentations on trabecular micro-bypass stents and corneal health, emphasizing Glaukos' commitment to glaucoma and corneal disorder treatments. The company aims to demonstrate its innovative technologies and engage with healthcare professionals throughout the event.
Glaukos Corporation (NYSE: GKOS) will announce its second quarter 2021 financial results on August 5, 2021, after market close. The management team will host a conference call and webcast at 1:30 p.m. PDT to discuss the results. Interested parties can access the live webcast via the company’s investor relations website and participate in the call by dialing the provided numbers and entering the conference ID. Glaukos specializes in innovative therapies for ocular conditions, including glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery.
Glaukos Corporation (NYSE: GKOS) responded to the CMS 2022 Medicare Physician Fee Schedule Proposed Rule released on July 13, 2021. This rule updates reimbursement policies for cataract surgery combined with the insertion of an aqueous drainage device. Two new CPT codes (669X2 and 669X1) will replace existing codes, with Glaukos estimating the 2022 physician fee for 669X2 at approximately $565.23, an increase of $34.25 from the previous fee. The company expressed disappointment over these proposed fees and plans to engage with ophthalmic societies during the public comment period.
Glaukos Corporation (GKOS) has completed patient enrollment and randomization in its FDA Phase 3 clinical trials for the iDose® TR sustained-release travoprost implant. The two prospective trials involve 1,150 subjects across 89 sites, aiming to assess the safety and efficacy of the iDose TR compared to timolol for treating open-angle glaucoma. Successful trial results are expected to support NDA submission in 2022 and FDA approval in 2023, potentially enhancing patient adherence to glaucoma treatments.